Evolus, Inc. (NASDAQ:EOLS) Insider Sells $77,512.40 in Stock

Evolus, Inc. (NASDAQ:EOLS) insider David Moatazedi sold 6,251 shares of Evolus stock in a transaction that occurred on Thursday, March 27th. The stock was sold at an average price of $12.40, for a total transaction of $77,512.40. Following the sale, the insider now owns 508,619 shares of the company’s stock, valued at approximately $6,306,875.60. This represents a 1.21 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Evolus Stock Performance

Shares of Evolus stock opened at $12.05 on Monday. The stock’s fifty day simple moving average is $13.66 and its 200 day simple moving average is $13.78. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The company has a market capitalization of $766.22 million, a PE ratio of -13.24 and a beta of 1.28. Evolus, Inc. has a 12 month low of $9.25 and a 12 month high of $17.82.

Wall Street Analysts Forecast Growth

A number of research firms have commented on EOLS. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 target price on shares of Evolus in a report on Wednesday, March 5th. HC Wainwright reissued a “buy” rating and issued a $27.00 target price on shares of Evolus in a research note on Wednesday, March 5th. Finally, Barclays boosted their target price on Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th.

Institutional Investors Weigh In On Evolus

Several large investors have recently modified their holdings of EOLS. KBC Group NV acquired a new position in shares of Evolus in the 4th quarter valued at approximately $49,000. IFP Advisors Inc boosted its holdings in shares of Evolus by 17,440.7% in the fourth quarter. IFP Advisors Inc now owns 4,736 shares of the company’s stock valued at $52,000 after buying an additional 4,709 shares during the period. KLP Kapitalforvaltning AS acquired a new position in Evolus in the 4th quarter worth $106,000. Rafferty Asset Management LLC acquired a new stake in shares of Evolus in the 4th quarter valued at about $115,000. Finally, Quantbot Technologies LP bought a new stake in shares of Evolus in the fourth quarter valued at about $118,000. 90.69% of the stock is currently owned by institutional investors.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.